This human monoclonal anti-PD-1 immunoglobulin (Ig) G4 antibody binds its receptor with high affinity, effectively blocking the interaction between PD-1 receptors on T cells and their ligands (PD-L1 and PD-L2) on tumor cells. Here, PDCD1 is linked to neoplasm.